WD-890 / Ningbo Wenda Pharma - LARVOL DELTA

Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of WD-890 tablets in Chinese healthy subjects (ChiCTR) - P1 | N=106 | Completed | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

New P1 trial • Dermatology • Immunology • Psoriasis

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Zhejiang Wenda Medical Technology Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

Recruitment of patients with moderate to severe psoriasis [Google translation] - "Patients with moderate to severe psoriasis were recruited for a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WD-890 tablets in the treatment of moderate to severe plaque psoriasis."

Enrollment status • Psoriasis

A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=106 | Completed | Sponsor: Zhejiang Wenda Medical Technology Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Aug 2024 | Trial primary completion date: Nov 2024 ➔ Aug 2024

Trial completion • Trial completion date • Trial primary completion date

A Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics，Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=106 | Recruiting | Sponsor: Zhejiang Wenda Medical Technology Co., Ltd.

New P1 trial